公开(公告)号：WO2004009034A2

公开(公告)日：2004-01-29

申请号：PCT/US2003/023031

申请日：2003-07-22

Applicant: ATTENUON, LLC.

Inventor： TERNANSKY, Robert, J. ,  MAZAR, Andrew ,  GLADSTONE, Patricia, L. ,  COUCOUVANIS, Dimitri ,  ALLAN, Amy, L. ,  O'HARE, Sean, M. ,  PRICE , Mellissa, L., P. ,  PIRIE-SHEPHERD, Steven, Robert ,  DONATE, Fernando

IPC: A61K

CPC classification number: C07D213/20 ,  C07C211/62 ,  C07C211/63 ,  C07C211/64 ,  C07C215/40 ,  C07C217/08 ,  C07C219/06 ,  C07C229/60 ,  C07C317/28 ,  C07D213/53 ,  C07D233/54 ,  C07D295/037 ,  C07D295/088

Abstract: The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation.

Abstract translation: 本发明提供了新型硫代钼酸盐衍生物，制备新型硫代钼酸盐衍生物的方法，新型硫代钼酸盐衍生物的药物组合物，使用新型硫代钼酸盐衍生物治疗异常血管形成相关疾病的方法，铜代谢障碍，神经变性疾病 ，肥胖症或NF-κB调节异常以及使用硫代钼酸盐衍生物的药物组合物治疗与异常血管形成，铜代谢紊乱，神经变性疾病，肥胖症或NF-κB失调有关的疾病的方法。

公开(公告)号：WO01014313A1

公开(公告)日：2001-03-01

申请号：PCT/US2000/023071

申请日：2000-08-23

IPC: A61K8/30 ,  A01N25/04 ,  A01N25/30 ,  A61K8/00 ,  A61K8/31 ,  A61K8/34 ,  A61K8/37 ,  A61K8/40 ,  A61K8/41 ,  A61K8/42 ,  A61K8/44 ,  A61K8/46 ,  A61K8/89 ,  A61K8/891 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q5/06 ,  A61Q5/12 ,  A61Q19/00 ,  A61Q19/10 ,  C07B43/00 ,  C07B61/00 ,  C07C213/02 ,  C07C213/08 ,  C07C215/08 ,  C07C215/40 ,  C07C217/08 ,  C07C221/00 ,  C07C225/00 ,  C10M133/06 ,  C10N30/12 ,  C11D1/46 ,  C11D1/62 ,  D06M13/328 ,  D06M13/463 ,  C07C223/00 ,  C07C229/00

CPC classification number: C07C215/40 ,  A61K8/44 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q19/00 ,  C07C215/08

Abstract: A process for making a tertiary amine ester of formula (I), the process comprising: (a) reacting a ketone or an aldehyde having formula (III) with a glycol to form a ketal or an acetal; (b) reacting the ketal or the acetal with acrylonitrile to form an ether nitrile; (c) reducing the ether nitril to a tertiary amine ketal or a tertiary amine acetal; (d) hydrolyzing the tertiary amine ketal or the tertiary amine acetal to a tertiary amine diol; and (e) esterifying the tertiary amine diol to the tertiary amine ester of formula (I), wherein R and R are each independently a hydrogen atom or a linear, branched, or cyclic alkyl, alkylene, alkaryl, or aryl-containing group containing 1 to 18 carbon atoms; and each R are each independently of one another fatty acid radicals having 6-22 carbon atoms. The process may optionally include the further step of: (f) protonating or quaternizing the tertiary amine ester of formula (I) to a protonated or quaternary amine ester of formula (II) wherein A is an inorganic or organic anion.

Abstract translation: 制备式（I）的叔胺酯的方法，该方法包括：（a）使酮或具有式（III）的醛与二醇反应以形成缩酮或缩醛; （b）使缩酮或缩醛与丙烯腈反应形成醚腈; （c）将醚腈还原成叔胺缩酮或叔胺缩醛; （d）将叔胺缩酮或叔胺缩醛水解成叔胺二醇; 和（e）将叔胺二醇酯化为式（I）的叔胺酯，其中R 1和R 2各自独立地为氢原子或直链，支链或环状的烷基，亚烷基，烷芳基， 或含有1至18个碳原子的含芳基; 并且每个R 3各自独立地为具有6-22个碳原子的另一个脂肪酸基团。 该方法可以任选地包括以下步骤：（f）将式（I）的叔胺酯质子化或季铵化为式（II）的质子化或季胺酯，其中A 1是无机或有机阴离子。

公开(公告)号：WO00056700A1

公开(公告)日：2000-09-28

申请号：PCT/GB2000/001090

申请日：2000-03-23

IPC: C07B37/04 ,  C07B37/12 ,  C07C45/46 ,  C07C45/69 ,  C07C211/65 ,  C07C215/40 ,  C07C219/06 ,  H01M6/16 ,  H01M10/36 ,  H01M10/39

CPC classification number: H01M10/399 ,  C07B37/04 ,  C07B37/12 ,  C07C45/46 ,  C07C45/69 ,  C07C211/65 ,  C07C215/40 ,  C07C219/06 ,  H01M10/36

Abstract: An ionic liquid having a melting point of no more than 60 DEG C, formed by the reaction of a quaternary ammonium compound of formula R R R R N X (I) or a mixture of two or more thereof; with a halide of zinc, tin or iron, or a mixture of two or more thereof; wherein R , R , and R , are each independently a C1 to C5 alkyl or a C6 to C10 cycloalkyl group, or wherein R2 and R3 taken together represent a C4 to C10 alkylene group, thereby forming with the N atom of formula (I) a 5 to11-membered heterocyclic ring, and wherein R , is a C6 to C12 alkyl or a cycloalkyl group, or a C1 to C12 alkyl or a cycloalkyl group substituted with at least one group selected from OH, Cl, Br, F, I, NH2, CN, NO2, COOR , CHO, COR and OR , wherein R is a C1 to C10 alkyl or cyloalkyl group, and X is a suitable counter-ion.

Abstract translation: 通过式R 1 R 2 R 3 R 4 N + X'的季铵化合物反应形成的熔点不超过60℃的离子液体 （I）或其两种或多种的混合物; 与锌，锡或铁的卤化物或其两种或更多种的混合物; 其中R 1，R 2和R 3各自独立地为C 1至C 5烷基或C 6至C 10环烷基，或其中R 2和R 3一起表示C 4至C 10亚烷基，从而形成 与式（I）的N原子为5至11元杂环，并且其中R 4为C 6至C 12烷基或环烷基，或C 1至C 12烷基或被至少一个 选自OH，Cl，Br，F，I，NH 2，CN，NO 2，COOR 5，CHO，COR 5和OR 5，其中R 5是C 1至C 10烷基或环烷基 ，而X - 是合适的抗衡离子。

公开(公告)号：WO99036167A1

公开(公告)日：1999-07-22

申请号：PCT/JP1999/000071

申请日：1999-01-12

IPC: B01F17/00 ,  B01F17/18 ,  C07C215/40 ,  C07C219/06 ,  B01F17/38 ,  C07C213/06 ,  C07K219/06 ,  D06M3/463

CPC classification number: C07C215/40 ,  B01F17/0042 ,  C07C219/06

Abstract: Cationic surfactants derived from amine derivatives of hexose alcohols which are reducing sugars of glucose or reducing alcohols of hexoses. These surfactants are obtained by converting 1-amino-hexose alcohols into quaternary salts and then esterifying with fatty acids. These surfactants are excellent in biodegradability.

Abstract translation: 衍生自己糖醇的胺衍生物的阳离子表面活性剂，其是葡萄糖的还原糖或己糖的还原醇。 这些表面活性剂是通过将1-氨基己糖醇转化成季盐，然后用脂肪酸酯化得到的。 这些表面活性剂的生物降解性优异。

公开(公告)号：WO1990005129A2

公开(公告)日：1990-05-17

申请号：PCT/US1989004511

申请日：1989-10-12

Applicant: PPG INDUSTRIES, INC.

Inventor： PPG INDUSTRIES, INC. ,  GOVINDAN, Cheruthur

IPC: C07C215/40

CPC classification number: C07D295/088 ,  C03C25/25 ,  C07C215/40 ,  C07C217/50 ,  C07C309/31 ,  C08K5/19 ,  C08K5/42 ,  C09K3/16 ,  D06M13/463

Abstract: Described are certain quaternary ammonium alkyl benzene sulfonate salts and certain quaternary ammonium alkane sulfonate salts, e.g., octyl dimethyl hydroxyethyl ammonium dodecyl benzene sulfonate and octyl dimethyl hydroxyethyl ammonium methane sulfonate which are useful as antistatic agents for synthetic polymer articles.

公开(公告)号：WO2017029274A1

公开(公告)日：2017-02-23

申请号：PCT/EP2016/069387

申请日：2016-08-16

Applicant: L'OREAL

Inventor： DALKO, Maria ,  HITCE, Julien

IPC: A61Q19/00 ,  A61K8/00 ,  C07C211/63

CPC classification number: C07C229/38 ,  A61K8/416 ,  A61Q19/00 ,  C07C215/40

Abstract: The present invention relates to the cosmetic use as moisturizer for keratin materials, preferably the skin, of one or more diethanolammonium derivatives corresponding to formula (I) below, and also the optical isomers and/or geometrical isomers thereof: (I)

Abstract translation: 本发明涉及作为一种或多种对应于下式（I）的二乙醇铵衍生物的角蛋白材料（优选皮肤）的保湿剂及其旋光异构体和/或几何异构体：（I）

公开(公告)号：WO2014114582A2

公开(公告)日：2014-07-31

申请号：PCT/EP2014050987

申请日：2014-01-20

Applicant: BAYER MATERIALSCIENCE AG

Inventor： HAGEN RAINER ,  FÄCKE THOMAS ,  MARKER VOLKER ,  BERNETH HORST ,  BRUDER FRIEDRICH-KARL ,  RÖLLE THOMAS ,  WEISER MARC-STEPHAN ,  HÖNEL DENNIS

IPC: C07C211/63

CPC classification number: B42D25/328 ,  B42D25/29 ,  B42D2033/20 ,  B42D2035/34 ,  C07C211/63 ,  C07C215/40 ,  C07C309/17 ,  C09D11/03 ,  C09D11/328 ,  C09D11/50 ,  G03H1/0011 ,  G03H1/0248 ,  G03H1/18 ,  G03H1/181 ,  G03H1/182 ,  G03H1/202 ,  G03H2001/186 ,  G03H2001/2271 ,  G03H2250/12 ,  G03H2250/34 ,  G03H2250/40 ,  G03H2250/44 ,  G03H2260/12

Abstract: The invention relates to a method for producing a security element having a holographic layer in which a hologram is arranged, characterized by at least the following steps: a) providing the holographic layer; b) exposing the holographic layer at least in sections via a master hologram to produce a hologram copy in the holographic layer; c) printing the holographic layer at least in sections with an ink, forming a printed feature, wherein the ink comprises the melt of a dye or a colorless component or a solvent and a dye dissolved therein or a colorless component dissolved therein; d) fixing the exposed holographic layer to produce the hologram in the holographic layer, wherein the printed feature and the hologram are arranged in the holographic layer such that the printed feature and the hologram overlap at least in sections. The invention further relates to a security feature which is produced or can be produced by said method.

Abstract translation: 本发明涉及一种方法，用于与全息层，其中的全息图被布置，其特征在于通过至少以下步骤制造的安全元件：a）提供所述全息层; b）至少一部分方式曝光上的主全息图，用于生成在全息层的副本全息全息层; c）至少有油墨的全息层的分批印刷以形成印刷特性，含有染料或无色组分或溶剂和溶解在其中的或溶解于其中的无色成分的染料的熔融油墨; D）固定在暴露的全息层的制造在全息层的全息图，其中，所述压力特性和全息图布置在全息层，使得压力特性和至少部分全息图重叠。 本发明还涉及一种安全特征，其可以通过该方法来生产或制造。

公开(公告)号：WO2014110308A1

公开(公告)日：2014-07-17

申请号：PCT/US2014/010955

申请日：2014-01-10

Applicant: SACHEM, INC.

Inventor： ENGEL, Tim ,  VAN LIER, Alfred

IPC: C07C211/63 ,  C11D3/30

CPC classification number: C09K15/22 ,  C07C209/90 ,  C07C211/62 ,  C07C211/63 ,  C07C211/64 ,  C07C213/10 ,  C07C215/40 ,  C07C215/72 ,  C07C215/90

Abstract: A composition including a quaternary onium hydroxide in a non-aqueous solvent, wherein the quaternary ammonium hydroxide has a concentration in the range from about 5% by weight to about 50% by weight of the composition; and imidazolidine-2,4-dione, wherein the imidazolidine-2,4-dione has a concentration in the range from about 10 to about 5000 parts per million of the composition.

Abstract translation: 一种在非水溶剂中包含季铵氢氧化物的组合物，其中季铵氢氧化物的浓度为组合物重量的约5％至约50％; 和咪唑烷-2,4-二酮，其中咪唑烷-2,4-二酮的浓度在组合物的百万分之10至约5000份之间。

公开(公告)号：WO2014083528A2

公开(公告)日：2014-06-05

申请号：PCT/IB2013/060474

申请日：2013-11-28

Applicant: KANDULA, Mahesh

Inventor： KANDULA, Mahesh

CPC classification number: C07C323/25 ,  C07C57/03 ,  C07C215/40 ,  C07C215/44 ,  C07C229/26 ,  C07C233/23 ,  C07C279/14 ,  C07C309/14 ,  C07C309/69 ,  C07C2601/14 ,  C07D213/66

Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable solvates and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula II, a salt of polyunsaturated fatty acid with at least one base HR and methods for the treatment of cardiovascular diseases and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, dyslipidemia, steatohepatitis and vascular diseases.

Abstract translation: 本发明涉及式I和式II化合物或其药学上可接受的溶剂合物及其水合物。 包含有效量的式I和式II化合物的药物组合物，具有至少一个碱基HR的多不饱和脂肪酸盐和用于治疗心血管疾病和脂质疾病的方法可以配制用于口服，口腔，直肠，局部 ，透皮，经粘膜，静脉内，肠胃外给药，糖浆或注射。 这样的组合物可用于治疗高甘油三酯血症，血脂异常，脂肪性肝炎和血管疾病。

公开(公告)号：WO2013148613A1

公开(公告)日：2013-10-03

申请号：PCT/US2013/033777

申请日：2013-03-26

Applicant: DOW GLOBAL TECHNOLOGIES LLC

Inventor： DEAVENPORT, Joseph, L.

IPC: A61Q5/12 ,  C07C215/40

CPC classification number: C07C215/40 ,  A61K8/416 ,  A61K2800/10 ,  A61Q5/00 ,  A61Q5/06 ,  A61Q5/12 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10

Abstract: Described are novel polycationic polyhydroxyl compounds for formula (I) and their uses in personal care compositions:

Abstract translation: 描述了式（I）的新型聚阳离子多羟基化合物及其在个人护理组合物中的用途：